-

Future Pak Withdraws Proposal to Purchase Vanda Pharmaceuticals Inc.

WIXOM, Mich.--(BUSINESS WIRE)--Consistent with the position indicated in its June 13, 2024 letter to Vanda Pharmaceuticals (“Vanda”), Future Pak LLC and its affiliates ("Future Pak") today announced that it is withdrawing its offer to acquire the Company, effective immediately, and will focus on other strategic objectives. This action comes after a continued lack of engagement from Vanda and the receipt of Vanda’s rejection of Future Pak’s final proposal.

About Future Pak

Future Pak is a privately-held contract manufacturer and packager of pharmaceutical and nutraceutical products. The company has access to retail, specialty and institutional customers through its expansive partner network. Leveraging its existing infrastructure, Future Pak seeks to make a positive impact on patients by utilizing its reliable supply chain and its quality-first approach. The company was incorporated in 1977 and is based in Wixom, Michigan.

Contacts

Media may contact Randi Kahn at Syneos Health Communications for more information:
631.697.8310
FuturePak_Media@syneoshealth.com

Industry:

Future Pak LLC

Release Versions
English

Contacts

Media may contact Randi Kahn at Syneos Health Communications for more information:
631.697.8310
FuturePak_Media@syneoshealth.com

More News From Future Pak LLC

Future Pak Issues Enhanced and Final Proposal to Acquire Vanda Pharmaceuticals Inc.

WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC and its affiliates ("Future Pak") today announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") in a good faith effort to acquire all outstanding shares of Vanda (the “Transaction”). Following the offer announced by Cycle Pharmaceuticals Ltd on June 6, 2024 to acquire Vanda as well as Future Pak’s improved offer, it is clear that Vanda’s Board should conduct a process to explore strategic...

Future Pak Increases Bid for Vanda Pharmaceuticals to Include CVRs in Addition to $7.25 to $7.75 Per Share in Cash

WIXOM, Mich.--(BUSINESS WIRE)--Future Pak LLC (“Future Pak”) confirms it increased its offer for all outstanding shares of common stock of Vanda Pharmaceuticals (“Vanda” or “the Company”) (NYSE: VNDA) to include Contingent Value Rights (“CVRs”) in addition to the cash consideration of $7.25 to $7.75 per share (the “Revised Proposal”), representing a potential increase of approximately $4.37 per share from the prior proposal announced on April 17, 2024. This increased offer, assuming full trigge...

Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash

WIXOM, Mich.--(BUSINESS WIRE)--Future Pak LLC (“Future Pak”) today announced that it has submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA), and confirms that its most recent proposal to acquire Vanda for cash consideration of $7.25 to $7.75 per share remains open for Vanda and its Board of Directors to consider. The current proposal implies a premium of 79.0% to 91.4% to Vanda's closing price...
Back to Newsroom